Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.

Autor:	Moussa, Charbel, Hebron, Michaeline, Xu Huang, Ahn, Jaeil, Rissman, Robert A., Aisen, Paul S., Scott Turner, R., Huang, Xu, Turner, R Scott
Předmět:	RESVERATROL ALZHEIMER'S disease ACTIVATORS (Chemistry) PLACEBOS NEURODEGENERATION METALLOPROTEINASES COGNITION disorders COMPARATIVE studies CYTOKINES ENCEPHALITIS GROWTH factors IMMUNITY LONGITUDINAL method RESEARCH methodology MEDICAL cooperation NERVE tissue proteins NONSTEROIDAL anti-inflammatory agents PEPTIDES PROTEOLYTIC enzymes PSYCHOLOGICAL tests RESEARCH ACTIVITIES of daily living STILBENE EVALUATION research BLIND experiment DISEASE complications PHARMACODYNAMICS THERAPEUTICS PSYCHOLOGY
Zdroj:	Journal of Neuroinflammation; 1/3/2017, Vol. 14, p1-10, 10p
Abstrakt:	Background: Treatment of mild-moderate Alzheimer's disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities of daily living (ADL) scores.Methods: For this retrospective study, we examined banked CSF and plasma samples from a subset of AD subjects with CSF Aβ42 <600 ng/ml (biomarker-confirmed AD) at baseline (N = 19 resveratrol-treated and N = 19 placebo-treated). We utilized multiplex Xmap technology to measure markers of neurodegenerative disease and metalloproteinases (MMPs) in parallel in CSF and plasma samples.Results: Compared to the placebo-treated group, at 52 weeks, resveratrol markedly reduced CSF MMP9 and increased macrophage-derived chemokine (MDC), interleukin (IL)-4, and fibroblast growth factor (FGF)-2. Compared to baseline, resveratrol increased plasma MMP10 and decreased IL-12P40, IL12P70, and RANTES. In this subset analysis, resveratrol treatment attenuated declines in mini-mental status examination (MMSE) scores, change in ADL (ADCS-ADL) scores, and CSF Aβ42 levels during the 52-week trial, but did not alter tau levels.Conclusions: Collectively, these data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and induces adaptive immunity. SIRT1 activation may be a viable target for treatment or prevention of neurodegenerative disorders.Trial Registration: ClinicalTrials.gov NCT01504854. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu